PHILADELPHIA – By comparing two species of ants, Shelley Berger, PhD, the Daniel S. Och University Professor at the University of Pennsylvania, and colleagues Danny Reinberg, PhD, New York University, and Juergen Liebig, PhD, Arizona State Univers…
A study posted today (Wednesday, August 25) at the online site of the journal Biology of Reproduction reports that exposure of pregnant female mice to the endocrine-disrupting chemical bisphenol A may produce adverse reproductive consequences on gen…
Using new DNA microarray technology, researchers have found significant changes in the expression pattern of hundreds of genes in heart muscle cells after mechanical pumps are used to take over from failing hearts. This finding represents a first step, they say, in a line of research that could help predict how heart failure patients will respond when supported by a left ventricular assist device (LVAD). These devices are employed when the heart’s left ventricle — the chamber of the heart that pumps blood throughout the body — is too weak to pump enough blood to nourish the body’s tissues. They have been used as successful short-term “bridges to heart transplant” and are increasingly being considered as long-term heart failure destination therapy, also known as “bridge to recovery.”
Oncologists are testing a new technique called gene expression profiling that subtypes each breast cancer tumor by its genetic defects so that doctors can tailor their treatment to inhibit that particular tumor. The researchers believe the technique could spare millions of women from needlessly receiving toxic chemotherapy, and they are leading a national clinical trial to study gene profiling. “Currently, we have no predictive model to determine who will respond to hormonal therapies and who won’t, so we prescribe chemotherapy as a backup measure to ensure the cancer’s demise,” said Matthew Ellis, M.D., Ph.D., director of the breast cancer program at Duke. “This one-treatment-fits-all approach leads to a huge amount of over treatment, with up to 50 percent of women unnecessarily receiving chemotherapy.”